Annovis Bio (NYSE:ANVS) Announces Earnings Results

Annovis Bio (NYSE:ANVS) posted its quarterly earnings data on Friday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), Zacks reports. During the same quarter last year, the business earned ($0.43) earnings per share.

Annovis Bio Price Performance

Shares of ANVS stock opened at $1.77 on Friday. Annovis Bio has a 12-month low of $1.53 and a 12-month high of $20.00. The business has a 50 day simple moving average of $2.99 and a 200 day simple moving average of $5.76. The firm has a market capitalization of $25.13 million, a price-to-earnings ratio of -0.40 and a beta of 1.65.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reiterated a “hold” rating on shares of Annovis Bio in a research report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Annovis Bio presently has an average rating of “Buy” and an average price target of $37.00.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.